Navigation Links
Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma

LONDON, October 30, 2014 /PRNewswire/ --

Investor-Edge has initiated coverage on the following equities: Organovo Holdings Inc. (NYSE MKT: ONVO), Medivation Inc. (NASDAQ: MDVN), Pharmacyclics Inc. (NASDAQ: PCYC), Synthetic Biologics Inc. (NYSE MKT: SYN), and Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD). Free research on these five companies can be accessed at: On Wednesday, October 29, 2014, the NASDAQ Composite ended at 4,549.23, down 0.33%, the Dow Jones Industrial Average declined 0.18%, to finish the day at 16,974.31, and the S&P 500 closed at 1,982.30, down 0.14%. The losses were broad based as seven out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 761.13, up 0.03%, with the index also advancing 6.25% in the previous three months. Register for your complimentary reports on these five stocks at:

Organovo Holdings Inc.'s stock lost 4.01%, to close the day at $6.22. The stock recorded a trading volume of 0.68 million shares, below its three months average volume of 0.93 million shares. The stock oscillated between $6.18 and $6.68 during the session. Over the last one month and since the start of this year, Organovo Holdings Inc.'s shares have declined 1.74% and 43.81%, respectively. However, the stock has gained 5.25% in the previous three trading sessions. The company's stock closed below its 50-day and 200-day moving averages. The stock's 200-day moving average of $7.73 is above its 50-day moving average of $6.75. Additionally, Organovo Holdings Inc. has a Relative Strength Index (RSI) of 55.16. Sign up and read the free notes on ONVO at:

On Wednesday, shares in Medivation Inc. recorded a trading volume of 0.90 million shares, lower than its three months average volume of 1.15 million shares. The stock ended the day at $99.55, which was 1.61% below its previous day's closing of $101.18, and registered an intraday range of $97.89 and $101.48. Shares of the company traded at a PE ratio of 368.70. Although Medivation Inc.'s shares have lost 0.70% in the last one month, it has surged 30.63% in the previous three months and 55.99% on YTD basis. The company's stock closed above its 50-day and 200-day moving averages of $95.01 and $77.90, respectively. Furthermore, shares of Medivation Inc. have an RSI of 60.46. The complimentary notes on MDVN can be downloaded as in PDF format at:

Pharmacyclics Inc.'s stock edged 0.94% higher, to close Wednesday's session at $132.08, after oscillating between $129.06 and $133.36. The stock recorded a trading volume of 0.88 million shares, close to its three months average volume of 0.91 million shares. Over the previous three trading sessions and the last one month, Pharmacyclics Inc.'s shares have advanced 6.79% and 9.57%, respectively. Additionally, from the beginning of 2014, the stock has surged 24.86%. The company's stock closed above its 50-day and 200-day moving averages. The stock's 50-day moving average of $118.58 is above its 200-day moving average of $112.29. Further, Pharmacyclics Inc. traded at a PE ratio of 118.99 and has an RSI of 70.39. Register for free on Investor-Edge and access the latest research on PCYC at:

Synthetic Biologics Inc.'s stock finished Wednesday's session 2.48% lower at $1.57. A total of 0.30 million shares were traded, which was below its three months average volume of 0.77 million shares. The stock moved between $1.51 and $1.64 during the session. Synthetic Biologics Inc.'s shares have fallen by 0.63% in the previous three trading sessions and 6.55% in the last one month. However, the stock has gained 2.61% on YTD basis. The company's shares closed below their 50-day and 200-day moving averages. Moreover, the stock's 200-day moving average of $1.97 is greater than its 50-day moving average of $1.90. Synthetic Biologics Inc.'s stock has an RSI of 47.13. The complete research on SYN is available for free at:

On Wednesday, shares in Ironwood Pharmaceuticals Inc. fluctuated between $13.13 and $13.84 before ending the session 1.74% lower at $13.56. The stock reported a trading volume of 0.79 million shares, below its three months average volume of 1.23 million shares. Ironwood Pharmaceuticals Inc.'s shares have advanced 2.26% in the previous three trading sessions, 1.27% in the last one month and 16.80% on YTD basis. The company's stock closed above its 50-day and 200-day moving averages of $12.82 and $13.35, respectively. Moreover, shares of Ironwood Pharmaceuticals Inc. have an RSI of 59.80. Free in depth research on IRWD is available at:


At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.




1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at]

5. For any urgent concerns or inquiries, please contact us at compliance [at]

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] for consideration.


Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.


Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.


Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference
2. Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon
3. Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells
4. The Hydroptere flies with Finesse: The hydrofoil trimaran Hydroptere will try for another nautical record with support from biotechnology leader Finesse Solutions
5. Biotech Equities Technical Analysis - ARIAD Pharma, Novavax, Galena Biopharma, Geron, and Celldex Therapeutics
6. Pre-market Biotech Picks - Gilead Sciences, MannKind, IsoRay, Orexigen Therapeutics, and Sunesis Pharma
7. Biotechnology For The Non Biotechnologist (France)
8. 2014 Top 50 Big Biotech Partnering and M&A Deal Trends
9. Fluonic to Present at Pharma/Biotech Conference
10. The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology ETF, SPDR S&P Biotech ETF, First Trust NYSE Arca Biotechnology Index Fund, Market Vectors Biotech ETF and PowerShares Dynamic Biotechnology & Genome Portfolio- GENOME
11. Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014
Post Your Comments:
(Date:5/4/2019)... ... 03, 2019 , ... Diopsys Inc, the world leader in ... vision test, a new full field electroretinography (ffERG) protocol designed to detect ... Americans will have glaucoma, with black Americans having the highest prevalence rate. This ...
(Date:5/2/2019)... ... ... Stay on top of current hot topics through free webinars presented by leading ... free, so be sure to register today to save your place! Participate in the ... our upcoming webinars: , CLINICAL TRIALS , May 7 – Oncology Clinical Trials – ...
(Date:4/25/2019)... ... ... albino, deaf Great Dane. His owners rescued him when he was four months old from ... impairment, he was always an active and playful pup. Frank bonded with his brother, another ... two grew, playtime became rougher and Frank ended up injuring his right rear leg. , ...
(Date:4/16/2019)... ... April 16, 2019 , ... On ... project partner, the U.S. Army Center for Environmental Health Research (USACEHR), with an ... In-Licensing/Out-Licensing.” , Blue Sources, a veteran-owned company located at the Frederick Innovative Technology ...
Breaking Biology Technology:
(Date:5/14/2019)... ... May 14, 2019 , ... IMMUNE 3D®, a privately held ... areas of autoimmunity, fibrosis and skin immunology. In addition, the company will leverage ... discovery efforts. , IMMUNE 3D®’s proprietary platform aims to study factors that ...
(Date:5/8/2019)... ... May 07, 2019 , ... ... into Forbes Technology Council, an invitation-only community for world-class CIOs, CTOs, and ... full-service biopharmaceutical cold chain engineering firm that guarantees confidence in a company’s ...
(Date:5/8/2019)... ... May 08, 2019 , ... ... a diameter of 200 microns and a lead-in fiber of 100 microns. With ... industry standard and positioning itself as the world leader in the development of ...
Breaking Biology News(10 mins):